501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Receives
Notice of Allowance for Cannabis Drug Detection Device
U.S.
Patent
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver,
British Columbia -- October
28, 2020
--
InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer
of the Cannabix Marijuana Breathalyzer devices
for law
enforcement and the workplace, reports that it has received a notice of
allowance
from the
United States Patent and
Trademark Office (USPTO) for its 2015 licensed
patent application, No. 14/689434
entitled,
"Cannabis Drug Detection Device". The Company and its
patent attorneys have been vigorously pursuing this original patent
application since its filing in the spring of 2015.
It should
be noted that a notice
of allowance from the USPTO does
not constitute a grant of patent. The Company will report on
future material developments
regarding
its "Cannabis Drug Detection Device" patent application in due
course.
Cannabix
Technologies is
on the
forefront in research and
development to create
point-of-care
breath
testing
technologies for
the
detection of ?9-tetrahydrocannabinol
("THC") - the psychoactive
component of marijuana that causes impairment.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing
accurate,
durable,
portable tools to market to enable
detection
of marijuana-impaired driving
offences on roads at a time when marijuana is becoming legal in
many global jurisdictions. Cannabix is working to develop
drug-testing devices that will detect THC- the psychoactive
component of marijuana that causes intoxication- using breath
samples. In particular, Cannabix is focused on developing breath
testing devices for detection of recent use of THC, in contrast to
urine testing for THC metabolite that requires an invasive
collection and reflects usage, days or even weeks earlier. The
devices will also be useful for other practical applications such
as testing employees in the workplace where impairment by THC can
be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including:
(i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.